/Thermo%20Fisher%20Scientific%20Inc_%20phone%20and%20site-by%20T_Schneider%20via%20Shutterstock.jpg)
Valued at a market cap of $159.1 billion, Thermo Fisher Scientific Inc. (TMO) is a global leader in serving science through innovative technologies and services. The company offers life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services worldwide. TMO is slated to announce its fiscal Q2 2025 earnings results before the market opens on Wednesday, Jul. 23.
Ahead of the event, analysts expect the Waltham, Massachusetts-based company to report an adjusted EPS of $5.22, down 2.8% from $5.37 in the year-ago quarter. However, the company has surpassed Wall Street's bottom-line estimates in the past four quarterly reports. In Q1 2025, Thermo Fisher exceeded the consensus adjusted EPS estimate by nearly 1%.
For fiscal 2025, analysts expect the medical equipment maker to report adjusted EPS of $22.34, up 2.2% from $21.86 in fiscal 2024. Looking forward to fiscal 2026, adjusted EPS is expected to grow 10.3% year-over-year to $24.65.
Shares of TMO have dipped 19.9% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) over 13% rise and the Health Care Select Sector SPDR Fund's (XLV) 6.3% decline over the same period.
Despite reporting better-than-expected Q1 2025 adjusted EPS of $5.15 and revenue of $10.4 billion, shares of TMO fell marginally on Apr. 23. The company lowered 2025 adjusted EPS guidance to a range of $21.76 to $22.84, below analysts’ average estimate. This downward revision was driven by expected impacts from the U.S.–China trade tensions, including a projected $400 million hit to China sales, which accounts for about 8% of its total business, along with rising costs from China-sourced components.
Analysts' consensus rating on Thermo Fisher stock is bullish, with a "Strong Buy" rating overall. Among 25 analysts covering the stock, 18 recommend a "Strong Buy,” three have a "Moderate Buy" rating, and four give a "Hold" rating. The average analyst price target for TMO is $548.32, indicating a potential upside of 28.2% from the current levels.
